0000022375 00000 n
The contribution of this metabolite to efficacy or toxicity is not known.There appears to be a relationship between plasma Amantadine concentrations and toxicity. It acts as a nicotinic antagonist and noncompetitive NMDA antagonist. Alcohol may also cause dose-dumping for at least one extended-release amantadine product.Alizapride: May diminish the therapeutic effect of Anti-Parkinson Agents (Dopamine Agonist).Alkalinizing Agents: May increase the serum concentration of Amantadine.Amisulpride (Injection): May diminish the therapeutic effect of Anti-Parkinson Agents (Dopamine Agonist).Amisulpride (Oral): May diminish the therapeutic effect of Anti-Parkinson Agents (Dopamine Agonist). 0000025587 00000 n
2011;61(4):574-582. Alternatively, temporary discontinuation of Amantadine hydrochloride capsules for several weeks, followed by reinitiation of the drug, may result in regaining benefit in some patients. The dose of Amantadine hydrochloride capsules may need reduction in patients with congestive heart failure, peripheral edema, or orthostatic hypotension Less frequently (1 to 5%) reported adverse reactions are: depression, anxiety and irritability, hallucinations, confusion, anorexia, dry mouth, constipation, ataxia, livedo reticularis, peripheral edema, orthostatic hypotension, headache, somnolence, nervousness, dream abnormality, agitation, dry nose, diarrhea and fatigue.Infrequently (0.1 to 1%) occurring adverse reactions are: congestive heart failure, psychosis, urinary retention, dyspnea, skin rash, vomiting, weakness, slurred speech, euphoria, thinking abnormality, amnesia, hyperkinesia, hypertension, decreased libido, and visual disturbance, including punctate subepithelial or other corneal opacity, corneal edema, decreased visual acuity, sensitivity to light, and optic nerve palsy.Rare (less than 0.1%) occurring adverse reactions are: instances of convulsion, leukopenia, neutropenia, eczematoid dermatitis, oculogyric episodes, suicidal attempt, suicide, and suicidal ideation Other adverse reactions reported during postmarketing experience with Amantadine usage include:coma, stupor, delirium, hypokinesia, hypertonia, delusions, aggressive behavior, paranoid reaction, manic reaction, involuntary muscle contractions, gait abnormalities, paresthesia, EEG changes, and tremor. 0000035554 00000 n
However, because of the potential for interference between these products, LAIV should not be administered within 2 weeks before or 48 hours after administration of Amantadine, unless medically indicated. 0000053887 00000 n
Amantadine may increase the serum concentration of Trimethoprim. If an atypical antipsychotic is necessary, consider using clozapine, quetiapine, or ziprasidone at lower initial doses, or a non-dopamine antagonist (eg, pimavanserin).Brivudine [INT]: May enhance the adverse/toxic effect of Anti-Parkinson Agents (Dopamine Agonist). Occasionally, patients whose responses are not optimal with Amantadine hydrochloride capsules at 200 mg daily may benefit from an increase up to 300 mg daily in divided doses.Depending upon creatinine clearance, the following dosage adjustments are recommended:Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].Dispense in a tight, light-resistant container as defined in the USP.The easiest way to lookup drug information, identify pills, check interactions and set up your own personal medication records. There are no well-controlled clinical studies demonstrating that treatment with Amantadine hydrochloride capsules, USP will avoid the development of influenza A virus pneumonitis or other complications in high risk patients.There is no clinical evidence indicating that Amantadine hydrochloride capsules, USP are effective in the prophylaxis or treatment of viral respiratory tract illnesses other than those caused by influenza A virus strains.The following points should be considered before initiating treatment or prophylaxis with Amantadine hydrochloride capsules, USP.Amantadine hydrochloride capsules, USP are indicated in the treatment of idiopathic Parkinson's disease (Paralysis Agitans), postencephalitic parkinsonism and symptomatic parkinsonism which may follow injury to the nervous system by carbon monoxide intoxication. Amantadine has an onset of action usually within 48 hours.The initial dose of Amantadine hydrochloride capsules is 100 mg daily for patients with serious associated medical illnesses or who are receiving high doses of other antiparkinson drugs. In a three litter, non-GLP, reproduction study in rats, Amantadine at a dose of 32 mg/kg/day (equal to the maximum recommended human dose on a mg/m The effect of Amantadine on embryofetal and peri-postnatal development has not been adequately tested, that is, in studies conducted under Good Laboratory Practice (GLP) and according to current recommended methodology.